Lars Fruergaard Jørgensen, president and CEO: "We delivered very solid performance in International Operations, driven by sales growth in all regions; meanwhile, sales in the USA were negatively impacted by inventory reductions. The global launch of Ozempic®, our new once-weekly GLP-1, is well on track and continues to gain market share. From a regulatory perspective, we achieved important milestones with the filing of oral semaglutide both in the USA and the EU. Based on the progress we made in the first quarter of 2019, we are on track to deliver on our outlook for the full-year.”
30 April - Novo Nordisk today announced that it will achieve its target to use only renewable electricity in its global production facilities by 2020. The announcement follows a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.
26 April - Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in a tablet taken once-daily, for the treatment of adults with type 2 diabetes.
“We are excited about the regulatory filing of oral semaglutide in Europe, the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes.”
Oral semaglutide has now been submitted for regulatory approval in
the US, the EU and Canada.
26 April - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Esperoct® (turoctocog alfa pegol, N8-GP) recommending marketing authorisation for the treatment of adolescents and adults with haemophilia A.
“We are confident that Esperoct® can provide a less burdensome and simple dosing regimen for prophylaxis and treatment of bleeding episodes, resulting in improved quality of life for people with haemophilia A.”
When Becky Furuta was told her cycling career was over due to her diabetes, she defied doctors' orders to rise to the top of her profession.
The International Committee of the Red Cross (ICRC), the Danish Red
Cross (DRC) and Novo Nordisk have partnered to tackle the growing
issue of chronic diseases that affect millions of people living in
humanitarian crises around the world. Focus will be on ensuring
efficient supply of low-cost human insulin in vials to Red Cross
globally; support for ICRC’s and DRC’s health programmes; 2-3 projects
to provide care to people with hypertension and diabetes in
humanitarian crises to be conducted within three years.
When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.
3 May - first quarter
9 August - first half
1 November - third quarter
The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.